Endoscopic Procedure Could Reduce Weight Regain

A study shows the Revita procedure may help patients maintain weight loss after discontinuing GLP-1 therapy.

Updated on Oct. 16, 2026 in Weight Loss

Gouache-painted editorial illustration showing a stylized endoscopic instrument tip near a textured organic passage, representing medical weight-loss treatment. — A new study found that the Revita endoscopic resurfacing procedure significantly reduced weight regain in patients who discontinued GLP-1 therapy. AI Illustration. Upload story photo >

Live Poll

Would you prefer a one-time procedural treatment over taking long-term weight loss medication?

As of the September 24, 2026 data cutoff, the Revita duodenal mucosal resurfacing procedure showed success in reducing weight regain among 308 adults following GLP-1 therapy. This endoscopic treatment offers a potential new option for those looking to maintain weight loss after discontinuing weight-loss medications.

Why it matters

Weight regain after stopping GLP-1 medications is a common obstacle for patients managing obesity. By remodeling the duodenal lining, this procedure aims to provide a durable approach to metabolic health that could help people sustain weight loss without continuous drug reliance.

In the REMAIN-1 randomized trial, 308 participants with a BMI of 30-45 saw significant results after receiving the Revita endoscopic procedure compared to a sham control. While the data shows lower weight regain, final 12-month pivotal findings are still expected in early 2027.

The players

Fractyl Health

A medical device company focused on developing metabolic therapies that address the root causes of chronic disease.

The details

The Revita procedure uses a specialized endoscopic method to perform duodenal mucosal resurfacing. By ablating the lining of the small intestine, the treatment aims to modulate the metabolic signaling pathways that influence hunger and insulin sensitivity. Study results showed dose-dependent effects, with participants receiving 20 cm or more of ablation experiencing a 53% reduction in weight regain compared to sham procedures.

September 24, 2026: The REMAIN-1 study reached its data cutoff.
Late Q4 2026: Fractyl Health plans to submit an FDA De Novo marketing application.
January 1, 2027: Category III CPT code 1122T takes effect.
Q1 2027: Researchers expect to release topline 12-month pivotal study data.
Early 2028: The company targets a potential US product launch.

Health Landscape

This development marks a shift toward device-based interventions that complement current pharmacotherapy for obesity. It represents a potential evolution from reliance on long-term GLP-1 medications toward procedures that may help patients sustain metabolic improvements.

If you are using GLP-1 medications, it is worth discussing potential long-term maintenance strategies with your doctor to understand upcoming clinical options. Monitor for updates in 2027 regarding safety data, as this remains an investigational procedure not yet available in the U.S.

The takeaway

The Revita procedure represents an experimental approach to preventing weight regain after stopping obesity medications. If you are concerned about maintaining weight loss, keep track of clinical trial milestones and consult your physician about the current standard of care for weight maintenance.

What happens next

The company expects to submit a De Novo marketing application to the FDA in late Q4 2026, followed by the release of 12-month pivotal data in Q1 2027.